Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy
Completed
United Therapeutics
Phase 3
2012-06-26
This is an international, multicenter, randomized, double-blind, placebo-controlled, event
driven study in subjects with pulmonary arterial hypertension.
Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Completed
United Therapeutics
Phase 2
2016-10-01
This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis
(SSc) and at least one calcinotic lesion of the hands that is palpable on physical
examination and also measureable on hand radiographs, at one single center. Each subject will
receive treprostinil orally for 12 months, and follow-up evaluations will be performed every
3 months. Our main objective is to determine whether oral treprostinil is safe, and effective
in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of
microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial
in the treatment of calcinosis in patients with SSc.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.